跳至主要内容
临床试验/NCT02472782
NCT02472782已完成不适用

Prospective,Non-interventional Study Investigating Possible Correlation Between Adherence to Postmenopausal and Steroid Induced Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication

251 Hellenic Air Force & VA General Hospital1 个研究点 分布在 1 个国家目标入组 851 人开始时间: 2015年5月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
851
试验地点
1
主要终点
Adherence to osteoporosis treatment assessed by medication possession ratio (MPR)

研究概览

简要总结

This is a study aiming to investigate a possible correlation between the parameters affecting the physicians' therapeutic choice with the patients' overall adherence to osteoporosis treatment. Secondary end-points include correlation between the parameters affecting the physicians' therapeutic choice and the patients' quality of life as well as the evaluation of the whole osteoporosis treatment approach of orthopedic surgeons in Greece (diagnostic means, use of diagnostic and treatment guidelines, methodology of follow - up).

详细描述

The study will include 100 orthopedic surgeons from the private sector working in private offices. The selection of this group of physicians resides on the fact that orthopedic surgeons working in private offices hold more than 60% of osteoporosis prescriptions in Greece.

Each physician will fill once a questionnaire regarding the parameters affecting his/her choice of osteoporosis treatment before entering any patient in the study. Following the completion of the questionnaire every physician will recruit up to 10 patients in the study who are eligible for osteoanabolic treatment (teriparatide) according to standard medical practice and the Greek osteoporosis treatment guidelines.

Each patient will receive teriparatide up to 24 months while he/she will fill the Greek EQ5D questionnaire on months: 0,12,24 or at early discontinuation. Adherence to treatment will be evaluated at the same time points as well as on monthly telephone interviews.

Both the adherence to treatment and the possible alteration of patients' quality of life (evaluated through the EQ5D questionnaire) during the study will be correlated with the parameters affecting the initial therapeutic decision of the physician

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
35 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Female patients with postmenopausal osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study.
  • Male patients ≥ 50 years old with idiopathic osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study.
  • Male and female patients with steroid-induced osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study.

排除标准

  • Prior use of teriparatide or PTH(1-84)
  • Hypersensitivity to teriparatide regimen.
  • Pregnancy and lactation.
  • Hypercalcamia.
  • Renal deficiency (eGFR < 30 ml/min).
  • Other bone metabolic diseases (including hyperparathyroidism and Paget's disease) except primary osteoporosis or steroid induced osteoporosis .
  • Uninterpretable increases of alkaline phosphatase (ALP)
  • Prior skeletal radiotherapy.
  • Skeletal malignancies or bone metastases

结局指标

主要结局

Adherence to osteoporosis treatment assessed by medication possession ratio (MPR)

时间窗: 2 years

Adherence to osteoporosis treatment assessed by medication possession ratio Adherence to osteoporosis treatment assessed by medication possession ratio (MPR) and correlation with the parameters affecting the physicians' therapeutic choices

次要结局

  • Quality of life assessed by EQ5D questionnaire(2 years)

研究者

发起方
251 Hellenic Air Force & VA General Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr Polyzois Makras

Deputy Director, Dpt of Endocrinology & Diabetes

251 Hellenic Air Force & VA General Hospital

研究点 (1)

Loading locations...

相似试验